Sanofi S.A. ADR Stock
Price
Target price
€44.40
€44.40
0.920%
0.4
0.920%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Sanofi S.A. ADR in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sanofi S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. ADR | 0.920% | 1.835% | 0.452% | -12.941% | -0.893% | 2.304% | 21.311% |
| Bayer AG ADR | 5.560% | -3.077% | -1.563% | -57.432% | -26.744% | -54.015% | -58.278% |
| Novo Nordisk A/S ADR | 0.000% | 0.855% | -1.255% | -25.079% | 25.800% | 90.939% | 174.419% |
| Roche Holding AG ADR | 1.280% | 0.872% | 0.165% | -19.062% | -10.263% | -17.988% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15
Upon an initial overview of Snof's financial statements, it seems that the company has a growing asset base and strong revenue figures over the years. The company appears to be in a favorable position in terms of cash reserves and increasing net income, suggesting positive financial performance. However, a more in-depth analysis is required to uncover the company's true financial health.
*Pros: *
Total Assets: As of December 31, 2022, Snof's total assets amounted to €124,585,000,000, showcasing a steady increase from €120,242,000,000 in 2021 and €114,529,000,000 in 2020. This growth indicates that the company is expanding and investing in its resources.
Comments
Sanofi (NASDAQ: SNY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for SNY provided by MarketBeat
Sanofi (NASDAQ: SNY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNY provided by MarketBeat
Sanofi (NASDAQ: SNY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNY provided by MarketBeat